| Clinical response (n) | ||||
|---|---|---|---|---|
| Indication | FR | PR | NR | Total |
| AZA/6MP Naive (LDAA without FDA exposure) | 82 | 7 | 16 | 105 |
| Switched from FDA to LDAA Poor response GI intolerance Hepatotoxicity Myelotoxicity “Flu-like” symptoms Other | 125 | 13 | 52 | 190 |
| 81 | 10 | 27 | ||
| 16 | n/a | 11 | ||
| 7 | 1 | 3 | ||
| 13 | 2 | 1 | ||
| 3 | n/a | 1 | ||
| 5 | n/a | 9 | ||